clinical trial · NCT05957536
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
D3 Bio (Wuxi) Co., Ltd·phase1·recruiting·n = 128
HER-2 Positive Advanced Solid TumorsD3L-001
brief summary
This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.
started
Sep 19, 2023
primary completion
Dec 19, 2028
completion
Dec 19, 2028
last updated
Mar 13, 2026
official title
A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol